INTRODUCTION
Encapsulation of ingredients in solid spherical particles has been applied to a diverse range of fields, including in printing, energy, architecture and flow analysis [1] [2] [3] [4] . This technique offers various advantages over use of nonencapsulated ingredients, including the following: (i) prevention of ingredients' dissolution in surrounding fluids and subsequent spreading because of separation from the external environment, (ii) safe handling of toxic ingredients, and (iii) easier handling of liquids and gases that are effectively solids in the encapsulated form 1, [5] [6] [7] . The functioning of a capsule depends on the properties of the materials the capsule shell is made from. In many industrial applications of capsules, nondegradable hard resins have been utilized as shell materials for stable packaging of ingredients. Several encapsulation techniques have been proposed for preparation of hard resin capsules [8] [9] [10] [11] . In the conventional methods, such as suspension polymerization and emulsion polymerization, capsules are prepared using emulsions of monomer droplets dispersed in an immiscible liquid [8] [9] [10] . There is a high risk with this emulsion system that ingredients in the monomer droplets could leak into the surrounding liquid during polymerization of the droplets 8, 11, 12 . Loss of ingredients results in low encapsulation efficiency and high manufacturing costs of the final products.
Mano were the first to successfully encapsulate ingredients in spherical hydrogel beads with almost no loss of the ingredients 13 . The high encapsulation efficiency (> 99%) was accomplished using a biologically inspired technique that was based on the natural phenomenon of spherical water droplet formation on highly hydrophobic lotus leaves. To mimic this, they placed a small volume of an aqueous solution containing a hydrophilic polymer and target ingredients on an artificial superhydrophobic plate.
Highly Efficient Encapsulation of Ingredients in Poly(methyl methacrylate) Capsules Using a Superoleophobic Material

SUMMARY
Increasing the efficiency of encapsulation of ingredients into spherical capsules can decrease the manufacturing costs of the capsules. Ingredients can be encapsulated with high efficiency (>99%) into nondegradable hard resin capsules prepared by polymerization of spherical droplets of trimethylolpropane trimethacrylate (TRIM) monomer placed on a superoleophobic material. Poly(methyl methacrylate) (PMMA) resin is a more versatile capsule material than poly-TRIM resin. In this study, the efficiency of encapsulation in PMMA resin capsules prepared from methyl methacrylate (MMA) monomer was investigated. To reduce the volatility of the MMA monomer, pre-polymerized MMA was used for capsule preparation. Although non-volatile α-tocopherol and doxorubicin could be encapsulated in the capsules with high efficiency by heat polymerization at 60°C for 3 h, the efficiency for volatile tetradecane was much lower (approximately 60%) because it evaporated. Furthermore, even when using pre-polymerized MMA, more than 70% of the prepolymer evaporated during polymerization. To prevent the evaporation of tetradecane and the prepolymer, ultraviolet photopolymerization was adopted because it was faster and could be conducted at a lower temperature. The photopolymerization prevented the evaporation of the prepolymer and increased the efficiency of encapsulation of tetradecane (approximately 90% efficiency). This polymerization system is effective for encapsulation of ingredients in PMMA capsules with high efficiency. The spherical droplets then gelled because of crosslinking of the polymer. Ingredients, including drugs, proteins and mammalian cells, were encapsulated with high efficiency because they did not leak from droplets through the air-liquid interface [13] [14] [15] . They also encapsulated a drug in capsules of the hydrophobic polymer (poly(D,Llactide--glycolide)) with high efficiency using a superoleophobic plate that could repel both hydrophilic and hydrophobic liquids 16 . The hydrophilic and hydrophobic polymers used to date in this method have all been degradable. By contrast, we have previously used a nondegradable hard resin for encapsulation of ingredients with high efficiency 17 . As detailed above, nondegradable resin capsules are of use in industrial applications for stable packaging of ingredients. In the research, capsules were prepared by placing droplets of trimethylolpropane trimethacrylate (TRIM) monomer containing the target ingredients on superoleophobic material for polymerization 17 . A silicone monolith called a "marshmallow-like gel" was used as a superoleophobic material 18 . The monolith was synthesized by a sol-gel method. The surface was densely covered with perfluoroalkyl groups.
The aim of this study was to investigate whether ingredients could be encapsulated with high efficiency in nondegradable poly(methyl methacrylate) (PMMA) resin capsules prepared from methyl methacrylate monomer (MMA) using the same methodology as our previous report. PMMA resin is a more versatile capsule material than poly-TRIM resin because of its higher flexibility and resistance to impact [19] [20] [21] . A major difference between MMA and TRIM monomers is their volatilities (vapour pressures MMA = 3.9 × 10 3 Pa and TRIM < 1.0 Pa at 20°C). Because of the high vapour pressure of MMA, PMMA capsules may not form during heat polymerization in our methodology as the monomer could evaporate. To reduce evaporation of the monomer, photopolymerization and the use of prepolymerized MMA were investigated as alternatives to heat polymerization and the monomer (Figure 1) . Two hydrophobic compounds (the antioxidant α-tocopherol and the phase change material -tetradecane) and the amphipathic anticancer drug doxorubicin were selected as model compounds for encapsulation to find ingredients appropriate for encapsulation in the capsules.
MATERIALS AND METHODS
Materials
MMA and -tetradecane were obtained from Kanto Chemical Co., Inc. (Tokyo, Japan). Doxorubicin, α-tocopherol and 2,2′-azobis(4-methoxy-2,4-dimethyl valeronitrile) (polymerization initiator) were purchased from Wako Pure Chemical Industries (Osaka, Japan). 2-Methyl-4′-(methylthio)-2-morpholinopropiophenone for photoinitiation of ultraviolet (UV) curing was kindly donated by Toyotsu Chemiplas Co. (Tokyo, Japan). The marshmallow-like gel was prepared using an established method 18 .
Pre-polymerization of MMA
The polymerization initiator 2,2′-azobis(4-methoxy-2,4-dimethyl valeronitrile) was dissolved in MMA at a mass fraction of 1.0%. The monomer was stirred at 50°C for 1 h in a nitrogen atmosphere to obtain a prepolymer. The viscosity of the prepolymer diluted with MMA at a ratio of 1.0:1.1 (weight basis) was 18 mPa×s at 25°C. A Brookfield DV-E rotational viscometer equipped with a ULA spindle (Brookfield Engineering Laboratories, Middleboro, MA, USA) was used for viscosity measurements. The prepolymer (not diluted with MMA) was kept at -80°C until required for preparation of capsules by heat or photo polymerization.
Preparation of Capsules by Heat Polymerization
Doxorubicin was dissolved in dimethyl sulfoxide (0.1% mass fraction). Tetradecane, α-tocopherol, or the dimethyl sulfoxide solution of doxorubicin was mixed with the MMA prepolymer at a mass ratio of 1:9. The mixed solution (10 µL) was placed on the marshmallow-like gel, and then solidified by heat polymerization in a nitrogen atmosphere at 60°C for 3 h. The recovery ratio of the capsules was determined using the following equation:
Recovery ratio of capsules (%) = (mass of solid capsules after polymerization/mass of droplets on the marshmallow-like gel before polymerization) × 100
After heat polymerization, the capsules were carefully ground and suspended in methanol (for α-tocopherol), acetone (for tetradecane) or dimethyl sulfoxide (for doxorubicin). The mixtures were sonicated to extract the ingredients from the capsules. The concentrations of the ingredients in the sample solutions were determined using a high-performance liquid chromatography system (Elite Lachrom, Hitachi Ltd., Tokyo, Japan) with a reversed-phase column (TSKgel ODS-80Ts column, 4.6 mm I.D. × 250 mm, Tosoh Co., Tokyo, Japan) for α-tocopherol, a gas chromatograph (Clarus500, PerkinElmer Co., Ltd., Waltham, MA, USA) equipped with a TC-1 capillary column (0.25 mm I.D. × 30 m, GL Sciences, Tokyo, Japan) for tetradecane, and a spectrometer (wavelength: 483 nm, UV-1700, Shimadzu Co., Tokyo, Japan) for doxorubicin. The encapsulation efficiency of each ingredient was calculated from the concentrations using the following equation:
Encapsulation efficiency (%) = (amount of ingredient in capsules after polymerization/amount of ingredient in prepolymer droplets on marshmallow-like gel before polymerization) × 100
Determination of Prepolymer Conversion to Solid Resin by UV Photopolymerization
The photoinitiator 2-methyl-4′-(methylthio)-2-morpholinopropiophenone was dissolved in the prepolymer at a concentration of 1.0% (mass fraction). An aliquot of this prepolymer (3 µL) was placed on the marshmallow-like gel, and then solidified by UV irradiation using 250 W UV lamp (SP-9 equipped with a SF/N optical fibre unit, Ushio Inc., Tokyo, Japan) placed at a distance of 1 cm from the gel surface in air at 20°C. A heat ray-absorbing filter was attached to the lamp to prevent increases in the temperature of the droplets. The capsules were dried under vacuum in the dark to remove residual volatile prepolymer until the mass of the capsules stayed constant for determination of prepolymer conversion to solid resin 22 . The conversion was determined using the following equation:
Prepolymer conversion to solid resin (%) = (mass of capsules after vacuum-drying/mass of prepolymer droplets on marshmallow-like gel before polymerization) × 100
Preparation of Capsules by UV Photopolymerization
Tetradecane, α-tocopherol, or the dimethyl sulfoxide solution of doxorubicin (0.1% mass fraction) was mixed with the MMA prepolymer containing the photoinitiator (1.0% mass fraction) at a mass ratio of 1:9. An aliquot of the prepolymer solution (3 µL) was placed on the marshmallow-like gel, and then solidified by UV irradiation for 20 min. The encapsulation efficiency of each ingredient was determined using the procedure described above.
Determination of Retention Ability of Capsules for Amphipathic Ingredient
Amphipathic doxorubicin-loaded PMMA capsules (0.1 g) prepared by photopolymerization were added to Ca 2+ and Mg
2+
-free phosphate-buffered saline (pH 7.4, 0.5 mL) and gently shaken at 20°C. At set intervals, the amounts of doxorubicin released from the capsules to the buffer solution were determined spectrophotometrically at a wavelength of 483 nm 23 .
Observation by Scanning Electron Microscopy (SEM)
The surfaces of capsules were sputtercoated with gold and observed under an SEM (S-3000N, Hitachi Ltd., Tokyo, Japan).
Statistical Analysis
All experiments were conducted at least in triplicate. Data are presented as mean ± standard deviation.
RESULTS AND DISCUSSION
It was first attempted to prepare PMMA capsules by heat polymerization of droplets of MMA monomer (not the prepolymer) without the target ingredients. However, capsules were not obtained because the monomer completely evaporated during polymerization at 60°C for 3 h. Consequently, a prepolymer of MMA was used to prevent this evaporation. The viscosity of the prepolymer diluted with MMA at a ratio of 1.0:1.1 (weight basis) was measured because it was difficult to measure the viscosity of the prepolymer directly due to its high viscosity. The viscosity of the diluted prepolymer was 18 mPa×s at 25°C (the viscosity of MMA before prepolymerization: < 1 mPa×s at 25°C). A prepolymer with even higher viscosity than the former prepolymer (not diluted with MMA) was not suitable for this method because it was too difficult to handle.
Preparation of Capsules by Heat Polymerization
The prepolymer (10 µL) containing the target ingredients formed spherical droplets with diameters of approximately 2.7 mm on the marshmallow-like gel with contact angles of ≥ 140° (Figure 2a) . After heat polymerization at 60°C for 3 h, the size decreased (Figure 2b) . The recovery ratios of capsules were between 20 and 30% for all ingredients, indicating that the decreased size was caused by evaporation of the prepolymer during heat polymerization. Considering that the mass fraction of the prepolymer in the droplets before polymerization was 90%, the low recovery ratios indicate that more than 70% of the prepolymer evaporated during heat polymerization. Evaporation of such a large proportion of the prepolymer is not suitable because it leads to lack of control of capsule size and strength.
Non-volatile ingredients (α-tocopherol and doxorubicin) were encapsulated with efficiencies of approximately 90% ( Table 1) . In a preliminary examination, radical species that were generated during heat polymerization denatured approximately 10% of α-tocopherol and doxorubicin in the droplets that could not be detected by the relevant techniques. Consequently, the results indicate that approximately 100% of the ingredients were encapsulated in the capsules. These high encapsulation efficiencies could be attributed to almost no leakage of the ingredients from the droplets through the air-liquid interface, and no permeation of the ingredients into the superoleophobic material. By comparison, the encapsulation efficiency of tetradecane was low (approximately 60%). This low efficiency could be attributed to evaporation of the aliphatic compound. To prevent evaporation of both the prepolymer and tetradecane, UV photopolymerization was used because the polymerization proceeds faster and at a lower temperature than heat polymerization 24 .
Preparation of Capsules by UV Photopolymerization
The relationship between UV photopolymerization time and prepolymer conversion to solid resin was investigated using the prepolymer without any ingredients. The volume of prepolymer droplets on the marshmallow-like gel was changed from 10 to 3 µL. These smaller droplets would enhance evaporation of the prepolymer. Even with these more severe conditions, prepolymer conversion reached 90% in a UV irradiation time (polymerization time) of ≥ 15 min (Figure 3) . Considering that more than 70% of the prepolymer in droplets evaporated during heat polymerization as described above, the photopolymerization system successfully prevented evaporation of the prepolymer. In subsequent experiments, the UV irradiation time was set at 20 min to ensure that adequate polymerization had occurred.
The photopolymerization produced capsules with increased sphericity compared with heat polymerization (Figure 2c) . The encapsulation efficiencies of α-tocopherol and doxorubicin for photopolymerization were similar to those for heat polymerization ( Table 1) . Like heat polymerization, photopolymerization (UV irradiation for 20 min) denatured approximately 10% of α-tocopherol and doxorubicin in the droplets. This shows that the two ingredients were encapsulated with almost no loss in this polymerization system. Importantly, compared with heat polymerization, the encapsulation efficiency of tetradecane with photopolymerization increased dramatically to approximately 90% ( Table 1) . These results indicate a potential of our methodology for production of tetradecane-laden capsules for heat storage 25 . In the photopolymerization system, a high-intensity UV lamp was used. Even though a heat ray-absorbing filter was used, a small amount of the rays could pass the filter. The heat rays would increase the temperature of droplets and cause evaporation of approximately 10% of the tetradecane from the droplets.
Retention Ability of Capsules for Amphipathic Ingredient
Doxorubicin is soluble in both hydrophobic and hydrophilic liquids because of the presence of hydrophobic and hydrophilic moieties in its molecular structure. We examined release of doxorubicin from capsules to evaluate their retention ability for amphipathic ingredients. The capsules were prepared by photopolymerization. Only 10% of the doxorubicin was released after incubation for 3 days, and further release was not observed after this time (Figure 4) . Release of amphipathic doxorubicin from the capsules in an aqueous environment would occur through diffusion of the substance in residual dimethyl sulfoxide in the capsules and water penetrating into the capsules. The high retention of the ingredient can be interpreted as a consequence of inhibition of the diffusion of doxorubicin in dimethyl sulfoxide and/or restriction of penetration of surrounding water into the capsules by the dense hydrophobic PMMA. It is assumed that there would be a small quantity of doxorubicin on the surface of the capsules that would be released. The retention of amphipathic doxorubicin in the capsules suggests that these capsules could be used in applications where retention of amphipathic ingredients in the capsules in an aqueous environment is important, such as encapsulated amphipathic fluorescent dyes used in particle image velocimetry for visualization of water flow in pipes 4 .
CONCLUSIONS
In this study, PMMA capsules were prepared by heat polymerization and UV photopolymerization of spherical droplets of a pre-polymerized MMA containing three ingredients, on a superoleophobic material. Heat polymerization caused evaporation of a large proportion of the prepolymer.
Although non-volatile α-tocopherol and doxorubicin could be encapsulated in the capsules with high efficiency by the polymerization, the efficiency for volatile tetradecane was much lower. UV photopolymerization reduced evaporation of the prepolymer and allowed high encapsulation efficiency for tetradecane. 
